Call your doctor before leaving home if you think you’ve been exposed to COVID-19 or have symptoms

Due to the presence of COVID-19 in our community, visitor restrictions are in place for all Duke clinics and hospitals. For your safety and the safety of others, we recommend patients do not bring a visitor to Duke clinics, if at all possible. If a visitor must accompany a patient, only one individual over 12 years of age is allowed. Patients and visitors will be screened for symptoms upon arrival. Individuals with flu-like symptoms are not allowed. View the complete list of Visitor Restrictions.

Effective immediately, Duke Health is prioritizing and rescheduling some non-emergent or non-critical surgeries, procedures, and appointments. Check our COVID-19 (Coronavirus) page for updates.

Dupilumab in Atopic Dermatitis - Clinical Trial

What is the Purpose of this Study?

The purpose of this study is to learn how Dupilumab affects the germs on your skin, water loss on your skin, and your immune system.
What is the Condition Being Studied?
Atopic Dermatitis; Eczema

Who Can Participate in the Study?

-18-65 years old
-Currently have least 3 spots of atopic dermatitis on your body
-Have used atopic dermatitis drugs on your skin in the past

Age Group

What is Involved?

There are two parts to this study.

Part One
If you choose to join this study, you will:
- Be randomized (like the flip of a coin) to either get a shot of the study drug (Dupilumab) or a shot without the drug
-Come to the clinic on days 1,3,and 7 and weeks 2, 3, 4 and 6 for:
---Shots in the muscle
---Blood draws
---Skin swabs

Part 2
-Both groups are now assigned to get the Dupilumab (study drug) shot every other week for 10 weeks
-- Be taught how to give yourself the shot every other week (or you can come in to have a medical professional do it)
---Come to the clinic for the same as before on weeks 11, and 16
-Complete a 30 minute phone call with the staff on week 16

Study Details

Full Title
Effect of Dupilumab (anti-IL4Ra) on the Host-Microbe Interface in Atopic Dermatitis
Principal Investigator
Protocol Number
IRB: PRO00100287
NCT: NCT03389893
Phase IV
Contact the Duke Recruitment Innovation Center